Eur Heart J:多学科讨论:极高浓度的“好”胆固醇也有害

2017-09-25 佚名 环球医学

丹麦科学家进行的两项前瞻性队列研究表明,极高的高密度脂蛋白胆固醇(HDL-C)与男性和女性高死亡率相关。目的:不同浓度的HDL-C与心血管疾病和死亡率负相关,但是遗传证据表明,极高浓度反而会导致更多的心血管疾病。研究者检验了假设,即极高浓度的HDL-C与较高的男性和女性全因死亡率相关。方法和结果:总共52268名男性和64240名女性从两项前瞻性基于人群的研究(哥本哈根市心脏研究和哥本哈根普通人群



丹麦科学家进行的两项前瞻性队列研究表明,极高的高密度脂蛋白胆固醇(HDL-C)与男性和女性高死亡率相关。

目的:不同浓度的HDL-C与心血管疾病和死亡率负相关,但是遗传证据表明,极高浓度反而会导致更多的心血管疾病。研究者检验了假设,即极高浓度的HDL-C与较高的男性和女性全因死亡率相关。

方法和结果:总共52268名男性和64240名女性从两项前瞻性基于人群的研究(哥本哈根市心脏研究和哥本哈根普通人群研究)中招募。745452人-年的随访期,男性的全因死亡数为5619[死亡率,17.1/1000人年(95% CI,16.7~17.6)],女性为5059[12.1/1000人年(11.8~12.4)]。男性和女性的HDL-C浓度和全因死亡率之间的相关性为U型,其中极高和极低浓度与较高的全因死亡风险相关。男性中,与最低的全因死亡率相关的HDL-C浓度为1.9mmol/L(95% CI,1.4~2.0)[73mg/dL(54~77)],女性为2.4mmol/L(1.8~2.5)[93mg/dL(69~97)]。与最低风险的患者相比,HDL-C为2.5~2.99mmol/L(97~115mg/dL)的男性的全因死亡率的多因素调整风险比为1.36(1.09~1.70),HDL-C≥3.0mmol/L(116mg/dL)的男性为2.06(1.44~2.95)。对于女性,HDL-C为3.0~3.49mmol/L(116~134mg/L)的风险比为1.10(0.83~1.46),HDL-C≥3.5mmol/L(135mg/dL)的女性为1.68(1.09~2.58)。

结论:普通人群中,具有极高HDL-C浓度的男性和女性反而具有较高的全因死亡率。这些结果需要在其他研究中证实。

多学科讨论记实:

本研究的结果可能对HDL-C浓度极高的个体有临床意义。首先,当HDL-C用于风险评估时,医生应意识到极高HDL-C者可能是全因死亡的高风险组。当前指南推荐风险评估,以及在初始降脂治疗之前测量HDL-C水平。本研究的结果表明,“HDL-C浓度越高越好”的普遍观点不适用于极高浓度,因为HDL浓度的整个范围中,HDL-C与全因死亡之间的关系不是线性的。第二,如果极高HDL-C与死亡高风险之间是因果关系,这些发现将增加“药物提高HDL-C至极高浓度”的不确定性。一些研制的CETP抑制剂能增加HDL-C至极高浓度,在本研究中与更高的死亡率相关。有趣的是,CETP抑制剂托彻普的研发中断,因为其增加死亡率,尽管这可能是由于脱靶效应。然而,当前结果指向一个替代解释:极高HDL-C本身就是高死亡率的原因。

由于这是一项观察性研究,不能确定极高HDL-C与较高死亡率之间的相关性是否为因果关系。此相关性可能是由于未测量的混杂因素或逆向因果关系。然而,排除了随访期第1~5年内去世的个体的分析结果似乎不能表明逆向因果关系。另一个局限性在于极高HDL浓度相对罕见;然而,2.5%最高HDL-C的男性的死亡风险全部增加。尽管纳入本研究的个体数量非常大,极高HDL-C组的人数较少,限制了统计功效,尤其是分层分析和病因特异性死亡分析,并在这些极端上影响模型拟合。最后,研究者仅纳入丹麦血统的白人个体,结果不一定适用于其他地理区域或种族。

原始出处:

Christian M.Madsen,Anette Varbo,et al.Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.European Heart Journal, 21 August 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-11-13 情途末路

    学习了.获益匪浅!感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-27 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-27 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=260923, encodeId=2792260923e2, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Mon Nov 13 06:46:36 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356513, encodeId=0d7c135651392, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439869, encodeId=3f7d143986910, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544468, encodeId=f1a91544468bf, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562698, encodeId=8b5c15626988c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 27 05:57:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247933, encodeId=fe5924e9335c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:01:03 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 yfjms

    学习了

    0

相关资讯

Redox Biol:OGC或可作为肝细胞癌治疗的一个新型靶标

研究结果显示,OGC的选择性过表达是HCC细胞的适应机制,以便在线粒体胆固醇负荷时提供足够的线粒体谷胱甘肽水平。该研究结果表明OGC或可作为HCC治疗的一个新型靶标。

Lancet:卡纳单抗——大幅降低心脏病风险

第一次,抑制炎症的药物帮助预防心脏病,这是一个全新降低胆固醇的方法。近期,抗肿瘤效应成为了研究人员们关注的对象,卡纳单抗是一种抗癌药物,研究人员对于它额外作用的研究打开一个新边疆,许多心脏病发生在胆固醇正常的人身上,这是因为慢性炎症导致了动脉阻塞。

重复 EUR HEART J:他汀类药物降低胆固醇可能很快就会成为过去!

每天使用他汀类药物降低胆固醇可能很快就会成为过去。一项新的研究揭示了疫苗如何成功降低小鼠中的“不良”胆固醇并减少动脉粥样硬化,这是斑块积聚引起的动脉狭窄。 该疫苗称为AT04A,已经进入人类临床试验,预计到今年年底将会有结果。

JACC:瑞舒伐他汀治疗儿童家族性高胆固醇血症的效果研究

纯合子家族性高胆固醇血症(HoFH),是一种罕见的遗传病,患者的低密度脂蛋白胆固醇(LDL-C)水平极高,并有进行性的动脉粥样硬化性心血管病。HoFH一旦诊断就应该接受他汀类药物治疗,但目前针对儿童HoFH的他汀类药物尚缺乏。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估瑞舒伐他汀治疗儿童HoFH的效果的临床研究。本研究是一个随机双盲对照研究,通过对比瑞舒伐他汀20mg和安慰剂的治疗效果,

Lancet:低密度脂蛋白究竟需要多低才是健康的?

新的分析显示,在高危人群中,达到低至低于10 mg / dL的超低LDL胆固醇水平可以安全地降低心血管事件风险。被称为PCSK9抑制剂的较新一类降胆固醇药物已经成为将LDL胆固醇显著降低至目前治疗目标以外的有效治疗方法。今年早些时候,由Brigham和女子医院调查人员进行临床试验的结果发现,当加入他汀类药物治疗时,PCSK9抑制剂evolocumab导致心血管事件风险显著降低,并且是安全的。在一个

JACC:如何减少他汀类使用中出现的肌肉毒性等副作用?

他汀类药物通过降低低密度脂蛋白或“不良”胆固醇来预防心脏病发作非常有效。然而,10%至20%的服用他汀类药物的患者报告肌肉相关症状,包括疼痛和痉挛,限制了他们使用推荐剂量。服用他汀类药物的患者心血管事件的风险很高,导致医疗保健成本上升。